Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,066,752
  • Shares Outstanding, K 1,035,419
  • Annual Sales, $ 24,556 M
  • Annual Income, $ 3,232 M
  • 36-Month Beta 0.37
  • Price/Sales 5.17
  • Price/Cash Flow 17.67
  • Price/Book 11.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.27
  • Number of Estimates 1
  • High Estimate 1.27
  • Low Estimate 1.27
  • Prior Year 1.34
  • Growth Rate Est. (year over year) -5.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
113.54 +9.21%
on 01/28/19
124.74 -0.59%
on 02/22/19
+6.91 (+5.90%)
since 01/22/19
3-Month
105.67 +17.35%
on 12/18/18
124.74 -0.59%
on 02/22/19
+11.77 (+10.49%)
since 11/21/18
52-Week
74.51 +66.42%
on 03/23/18
124.74 -0.59%
on 02/22/19
+46.81 (+60.64%)
since 02/22/18

Most Recent Stories

More News
Merck to Buy Immunotherapy Developer Immune Design for $300M

Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.

MRK : 80.77 (+1.18%)
LLY : 124.00 (+1.04%)
IMDZ : 5.83 (+0.17%)
BMY : 50.98 (+1.70%)
Look for Shares of Eli Lilly & Co to Potentially Pullback after Yesterday's 1.10% Rise

Eli Lilly & Co (NYSE:LLY) traded in a range yesterday that spanned from a low of $123.94 to a high of $124.42. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of...

LLY : 124.00 (+1.04%)
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates

Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).

NVO : 49.78 (+0.24%)
MRK : 80.77 (+1.18%)
LLY : 124.00 (+1.04%)
IMDZ : 5.83 (+0.17%)
ABBV : 80.02 (+1.61%)
RHHBY : 34.7300 (+0.51%)
PFE : 42.96 (+1.95%)
Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review

The index endured a holiday-shortened but volatile week.

MSFT : 110.97 (+1.43%)
JPM : 105.00 (-0.45%)
MRK : 80.77 (+1.18%)
CAT : 138.68 (-0.14%)
WBA : 70.43 (-0.06%)
PG : 100.25 (+0.47%)
LLY : 124.00 (+1.04%)
GS : 196.00 (-0.18%)
PFE : 42.96 (+1.95%)
BA : 424.05 (+1.55%)
WMT : 99.55 (+0.16%)
New Research Coverage Highlights FedEx, Honeywell International, Nielsen Holdings Plc, Changyou, J.B. Hunt Transport Services, and Eli Lilly -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FedEx Corporation (NYSE:FDX),...

CYOU : 21.60 (-0.96%)
HON : 153.20 (+0.39%)
JBHT : 109.11 (-2.10%)
LLY : 124.00 (+1.04%)
FDX : 180.49 (-0.98%)
NLSN : 26.10 (+0.89%)
Option-trading strategies on Freeport-McMoRan, Eli Lilly and Co., Riot Blockchain Inc., Twitter Inc. and Uniti Group Inc.

InvestorsObserver issues critical PriceWatch Alerts for FCX, LLY, RIOT, TWTR, and UNIT.

UNIT : 9.23 (-7.61%)
TWTR : 31.71 (+3.09%)
LLY : 124.00 (+1.04%)
FCX : 13.22 (+1.54%)
RIOT : 3.95 (+12.22%)
Allergan Responds to Investor's Call for CEO/Chair Role Split

Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.

EOLS : 24.65 (-0.04%)
LLY : 124.00 (+1.04%)
AGN : 136.70 (+0.07%)
TEVA : 17.25 (unch)
Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study

Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.

LLY : 124.00 (+1.04%)
TEVA : 17.25 (unch)
REGN : 422.52 (+0.93%)
PFE : 42.96 (+1.95%)
Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo

Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.

BAYRY : 18.9100 (-1.33%)
LLY : 124.00 (+1.04%)
GSK : 40.55 (+0.02%)
BMY : 50.98 (+1.70%)
Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why

Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.

AZN : 40.94 (+1.26%)
MRK : 80.77 (+1.18%)
LLY : 124.00 (+1.04%)
INCY : 84.85 (+1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade LLY with:

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 125.89
1st Resistance Point 124.94
Last Price 124.00
1st Support Level 122.85
2nd Support Level 121.71

See More

52-Week High 124.74
Last Price 124.00
Fibonacci 61.8% 105.55
Fibonacci 50% 99.63
Fibonacci 38.2% 93.70
52-Week Low 74.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar